Bovie Medical Corporation — FY2014 Form 10-K
Entity and period: The filing is for Bovie Medical Corporation (NYSE MKT: BVX), not Apyx Medical Corp. It reports the fiscal year ended December 31, 2014; amounts below are in U.S. dollars unless stated otherwise.
Business context
Bovie develops, manufactures, and markets electrosurgical equipment and related medical products, including cauteries and medical lighting. Its newer J-Plasma helium-plasma surgical technology was in early commercialization. Most established products are sold through distributors, OEM arrangements, or private-label channels.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $27.681 million | $23.660 million |
| Gross profit / margin | $8.992 million / 32.5% | $9.198 million / 38.9% |
| Operating loss | $5.849 million | $3.666 million |
| Net loss | $17.282 million | $4.339 million |
| Net loss attributable to common shareholders | $18.214 million | $6.994 million |
| Net cash used in operating activities | $0.417 million | $2.536 million |
| Cash and cash equivalents at year-end | $5.733 million | $7.924 million |
| Working capital | $11.599 million | $16.910 million |
FY2014 revenue rose 17.0%, led by electrosurgical products (+26.8%) and OEM revenue (up to $3.150 million from $1.484 million). J-Plasma revenue was $209,368, nearly five times FY2013, but still small relative to total sales. International sales were 15.7% of revenue, down from 17.7%.
Operating cash use improved year over year, but cash declined by $2.191 million. The balance sheet reported $0.899 million of restricted cash in addition to $5.733 million of cash and equivalents. Bovie had $3.412 million of mortgage debt at year-end; the loan bears interest at LIBOR plus 3.5%, is secured by the Clearwater facility and accounts receivable, and requires minimum liquidity of $750,000. The filing also reports $12.613 million of derivative liabilities and $3.190 million of Series A preferred stock outside stockholders’ equity.
Material changes and unusual items
- Gross margin fell 6.4 percentage points. Management attributed the decline mainly to excess and obsolete inventory; the company recorded approximately $2.0 million of related inventory charges during 2014.
- The net loss included a $7.285 million loss from changes in fair value of warrant liabilities, a non-cash valuation item. Warrant liabilities rose to $12.613 million, with valuation based partly on significant unobservable inputs.
- A full valuation allowance was established against finite-life net deferred tax assets; management said this increased the 2014 income-tax provision by $6.0 million. The reported deferred tax asset was eliminated, with a $0.564 million deferred tax liability at year-end.
- In March 2014, Bovie refinanced its prior industrial revenue bond and PNC obligations with a $3.592 million Bank of Tampa mortgage loan, and paid to terminate the interest-rate swap. The year-end mortgage balance was $3.412 million.
- Quarterly FY2014 revenue was $7.466 million in Q4; Q4 gross profit was $2.441 million and net loss attributable to common shareholders was $5.454 million, or $0.31 per basic share.
Outlook, risks, and contingencies
Management described continued investment in J-Plasma commercialization and product development, cautioning that these investments could weigh on near-term profitability and cash flow, particularly over the next 12 to 24 months; future commercial success is not assured. Management expected 2015 research and development spending to remain near the 2014 level. The filing gave no quantified revenue, earnings, or cash-flow guidance.
J-Plasma had FDA clearance, and the Bovie Ultimate generator received FDA clearance in December 2014; J-Plasma also received a CE mark in December 2014. Management reported 28 ordering accounts for J-Plasma at year-end and more than 20 hospital value-analysis evaluations. A direct sales organization was built to support adoption. New laparoscopic electrodes were planned for launch in Q1 2015.
- Revenue and receivables are concentrated: the ten largest customers represented 61.0% of FY2014 sales, and one distributor accounted for 13.9%. Loss of major distributors or OEM business could materially affect results.
- The company relies on certain sole-source suppliers and a Bulgarian supplier for many generator and accessory components; disruptions could impair production.
- Commercial adoption, regulatory compliance, product safety, intellectual-property disputes, and competition are material risks. The filing also identifies potential dilution from preferred shares, warrants, and options.
- The 2013 financing included 3.5 million Series A preferred shares accruing a 6% dividend and warrants to purchase 5.25 million common shares, plus placement-agent warrants. Preferred shares may become redeemable at the holders’ option beginning December 2017.
- A stockholder derivative action was settled, with final court approval in October 2014. The company disclosed other ordinary-course claims but said outcomes are uncertain.
Important facts for investors to verify
- Whether J-Plasma ordering accounts and evaluations convert into sustained sales, and the associated commercialization costs.
- Cash availability and compliance with the mortgage liquidity covenant, including the treatment of restricted cash.
- The potential effects of preferred-stock redemption rights, accrued dividends, warrant remeasurement, and possible equity dilution.
- Whether gross margins recover after the inventory charges and whether further inventory reserves are needed.
- Customer and supplier concentration, including the status and durability of major OEM and distributor relationships.